TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00876395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab, 2 mg/kg weekly was used intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab, 2 mg/kg weekly was used intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 80 mg/m2 weekly was used intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel, 80 mg/m2 weekly was used intravenously.
Study: NCT03439839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iptacopan
Description: iptacopan bid orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iptacopan
Description: iptacopan bid orally administered

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care (SoC) is defined as an antibody with anti C5 activity. At the time of study start, eculizumab was the only available SoC; eculizumab will be hereafter referred to as SoC.
Study: NCT05259215

Intervention type: OTHER
Intervention: physiotherapy
Description: Standard usual care physiotherapy after stroke

Intervention type: OTHER
Intervention: physiotherapy
Description: Standard usual care physiotherapy after stroke
Study: NCT01850329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computed-assisted information program
Study: NCT01369303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
Study: NCT02150005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Study: NCT02235740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
Study: NCT03948490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMind iPad app
Description: Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy SMS texting
Description: Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person cognitive rehabilitation
Description: The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth cognitive rehabilitation
Description: The telehealth cognitive rehabilitation will take place over secure UCSF Zoom. It will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning
Study: NCT02100631

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PXVX0200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01689038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F17464
Description: Single dose
Study: NCT02338986

Intervention type: DRUG
Intervention: Plasma
Description: Plasma
Study: NCT03684655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Description: \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
Study: NCT03367156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03282396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT01527669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LipoCol Forte capsules
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin Tablet
Description: The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
Study: NCT06229938

Intervention type: OTHER
Intervention: Passive leg raise manoeuvre
Description: Stroke volume measurements are performed with the Nexfin hemodynamic monitor and the volemic state measurement is based on the principle of the classic passive leg raise test. The Nexfin monitor (Nexfin CC, Edwards Life Sciences, the Netherlands) uses a small inflatable cuff around the index finger of the right hand, to measure the blood pressure, and uses a specific algorithm to calculate the stroke volume.~First a baseline measurement is performed during supine position while the patient is lying in bed. Next, the head end will be lowered until lying flat, and the legs will be passively raised until the lower end of the bed is 30 degrees elevated. The change in stroke volume following the passive leg raise test is used to assess fluid responsiveness. An increase of 10% indicates a fluid responsive status or hypovolemia.
Study: NCT04309513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI score to motivate physical activity
Description: Participants will be encouraged to work up to and maintain the highest PAI score possible, with 100 being the ideal, as measured by a wearable device. Their devices and an accompanying app will provide them with an ongoing real time calculation of the PAI score.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Counter to motivate physical activity
Description: Step Counter to motivate physical activity
Study: NCT01847209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery (VATS) wedge resection
Study: NCT02329158

Intervention type: DRUG
Intervention: 6% hydroxyethyl starch
Study: NCT00576758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab (RO5072759)
Description: 1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
Study: NCT03408132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE203799
Description: FE203799 5 mg subcutaneous once weekly
Study: NCT00576758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.
Study: NCT00872118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Socially Anxious Drinkers (BISAD)
Description: integrated alcohol and social anxiety individual intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Alcohol Skills Building and Education Program
Description: alcohol-focused group intervention
Study: NCT02606305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT01498094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen Therapy
Description: Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard low flow oxygen
Description: Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
Study: NCT01548144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (Xalkori)
Description: Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (Xalkori)
Description: Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib (Xalkori)
Description: Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1.
Study: NCT03108781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavender Oil
Description: Lavender Oil twice a day; one month on the face and one month on the legs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lavender Oil
Description: Lavender Oil twice a day; one month on the face and one month on the legs
Study: NCT02606305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT00563173

Intervention type: DRUG
Group type: OTHER
Intervention: CHRONVAC-C®
Description: DNA vaccine, solution for injection, i.m. administration in combination with electroporation

Intervention type: DRUG
Group type: OTHER
Intervention: CHRONVAC-C®
Description: DNA vaccine, solution for injection, i.m. administration in combination with electroporation

Intervention type: DRUG
Group type: OTHER
Intervention: CHRONVAC-C®
Description: DNA vaccine, solution for injection, i.m. administration in combination with electroporation
Study: NCT02199587

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Presence of medical clown during endocrine test
Study: NCT04461392

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise test
Description: * Cardiorespiratory exercise test to evaluate the exercise tolerance~* Cardiac imaging for the assessment of the left atrium anatomy and function.
Study: NCT01609972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Non-inferior comparison of implantable spinal cord stimulators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: Non-inferior comparison of implantable spinal cord stimulators
Study: NCT01431976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal
Description: No comparison
Study: NCT00970944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice daily.
Study: NCT02705170

Intervention type: PROCEDURE
Intervention: index of microvascular resistance
Description: Measurement of the index of microvascular resistance in the left anterior descending artery
Study: NCT03597867

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Artificial tears for 3 days preoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicloftil
Description: Dosing of drug 3 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevanac
Description: Dosing of drug 3 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indom
Description: Dosing of drug 3 days prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yellox
Description: Dosing of drug 3 days prior to surgery
Study: NCT03499132

Intervention type: PROCEDURE
Intervention: anesthesia
Description: Different anesthetic procedures

Intervention type: PROCEDURE
Intervention: anesthesia
Description: Different anesthetic procedures

Intervention type: PROCEDURE
Intervention: anesthesia
Description: Different anesthetic procedures

Intervention type: PROCEDURE
Intervention: anesthesia
Description: Different anesthetic procedures
Study: NCT03108781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunflower oil
Description: placebo twice a day (sunflower oil); one month on the face and on month on the legs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: placebo twice a day (sunflower oil); one month on the face and on month on the legs
Study: NCT02324543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV on days 4 and 11 of a 21 day cycle
Study: NCT02394275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: All eligible patients will receive fecal microbiota transplant
Study: NCT01798290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: narrative medicine: reading workshop

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: critical reading
Study: NCT03424304

Intervention type: DEVICE
Group type: OTHER
Intervention: Excel V™ Laser With Green Genesis
Description: Subject(s) will receive treatments with a Cutera Excel V™ Laser
Study: NCT01717248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
Study: NCT03915067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX® purified neurotoxin complex
Description: BOTOX® superficial intramuscular injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX® purified neurotoxin complex
Description: BOTOX® superficial intramuscular injections.
Study: NCT01365221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
Study: NCT04568330

Intervention type: OTHER
Group type: OTHER
Intervention: best support care
Description: Best support care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moisture cream
Description: BSC plus moisture cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% urea-based cream
Description: BSC plus 10% urea-based cream.
Study: NCT04643184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management Program
Description: Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
Study: NCT02714179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol was given intravenously in both group at different times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol was given intravenously in both group at different times
Study: NCT03915067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections.
Study: NCT01561105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: IMPACT is a collaborative care management program for late-life depression